Protein produced in sepsis lowers blood pressure, treatment identified to reverse effects

April 23, 2020

(Philadelphia, PA) - Overreaction is rarely useful, and in the case of the human immune system, it can be outright deadly. When the body overreacts to an infection, the result is sepsis - a life-threatening condition that frequently leads to acute organ dysfunction, including deterioration of the heart and blood vessels, which make up the cardiovascular system. A major indication that the cardiovascular system is failing in sepsis is a drop in blood pressure, the only treatment for which is fluid replacement.

Now, in a new study published online April 23 in the journal JCI Insight, scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) show that when a molecule known as c-Jun N-terminal kinase (JNK) becomes active in sepsis, it increases the production of a protein called B-type natriuretic peptide (BNP) - the more BNP that is produced in sepsis, the greater the deterioration of cardiovascular function. But perhaps more significantly, in mice, the researchers show that JNK and BNP activity can be halted, reversing cardiovascular damage and reducing the risk of death from sepsis.

"Low blood pressure is characteristic of the most severe form of sepsis, known as septic shock, in which fluid loss and decreased oxygen and nutrient delivery to tissues severely damages organ function," explained Konstantinos Drosatos, PhD, Assistant Professor of Pharmacology and Assistant Professor in the Center for Translational Medicine, the Center for Metabolic Disease Research, and the Alzheimer's Center at LKSOM and senior investigator on the new study.

In previous work, Dr. Drosatos's team found out why heart cells decrease their energy output in sepsis. They also knew from earlier studies that blocking JNK activation could correct cardiovascular dysfunction and lower BNP levels in an animal model of sepsis. The new study expands on this work and demonstrates how treatments aimed at improving cardiovascular function facilitate communication between the heart and blood vessels, which circulate blood throughout the body.

The researchers carried out their investigation of JNK and BNP activation in heart cells and in a mouse model of sepsis. Their experiments revealed a direct relationship between the two molecules, in which a c-Jun activating protein attaches to the gene that encodes BNP. When this happens, the gene is switched on, resulting in the production of BNP. In sepsis, the BNP-encoding gene is always "on," explaining why BNP protein is secreted in excess by the heart.

In separate experiments, the researchers blocked either JNK activation, using a chemical inhibitor, or BNP activity, using an antibody against the protein that was developed in Dr. Drosatos's laboratory. Both approaches restored blood pressure in septic mice, though JNK inhibition yielded the most robust benefits. Inhibition of either molecule also led to improvements in survival from sepsis.

"At a clinical level, JNK or BNP inhibition could stabilize blood pressure and give other medications, such as antibiotics, time to work," Dr. Drosatos explained. "This strategy could be used alongside current supportive strategies, which attempt to slow or prevent fluid loss to stabilize blood pressure."

In follow-up research, Dr. Drosatos is working closely with Nina Gentile, MD, Professor of Emergency Medicine at LKSOM to explore potential clinical applications of BNP inhibition. "We hope to develop innovative treatments that will work in patients to combat septic shock," Dr. Drosatos said.

Another important next step is to explore whether the new monoclonal antibody against BNP can be used as an intervention to treat low blood pressure in sepsis patients. "In light of the ongoing COVID-19 global pandemic, the association of COVID mortality with viral sepsis, and elevated BNP plasma levels in critical COVID-19 patients, the topic of BNP inhibition is very timely," Dr. Drosatos noted.
The new study was carried out primarily by Matthew Hoffman, a graduate student in the MD-PhD program at LKSOM. Other investigators who contributed to the study include Ioannis D. Kyriazis, Alexandra Dimitriou, and Walter J. Koch, the Center for Translational Medicine at LKSOM; and Santosh K. Mishra, Department of Molecular Biomedical Sciences, North Carolina State University.

About Temple Health

Temple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHS's physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

Temple University Health System

Related Blood Pressure Articles from Brightsurf:

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers.

High blood pressure treatment linked to less risk for drop in blood pressure upon standing
Treatment to lower blood pressure did not increase and may decrease the risk of extreme drops in blood pressure upon standing from a sitting position.

Changes in blood pressure control over 2 decades among US adults with high blood pressure
National survey data were used to examine how blood pressure control changed overall among U.S. adults with high blood pressure between 1999-2000 and 2017-2018 and by age, race, insurance type and access to health care.

Transient increase in blood pressure promotes some blood vessel growth
Blood vessels are the body's transportation system, carrying oxygen and nutrients to cells and whisking away waste.

Effect of reducing blood pressure medications on blood pressure control in older adults
Whether the amount of blood pressure medications taken by older adults could be reduced safely and without a significant change in short-term blood pressure control was the objective of this randomized clinical trial that included 534 adults 80 and older.

Brain blood flow sensor discovery could aid treatments for high blood pressure & dementia
A study led by researchers at UCL has discovered the mechanism that allows the brain to monitor its own blood supply, a finding in rats which may help to find new treatments for human conditions including hypertension (high blood pressure) and dementia.

Here's something that will raise your blood pressure
The apelin receptor (APJ) has been presumed to play an important role in the contraction of blood vessels involved in blood pressure regulation.

New strategy for treating high blood pressure
The key to treating blood pressure might lie in people who are 'resistant' to developing high blood pressure even when they eat high salt diets, shows new research published today in Experimental Physiology.

Arm cuff blood pressure measurements may fall short for predicting heart disease risk in some people with resistant high blood pressure
A measurement of central blood pressure in people with difficult-to-treat high blood pressure could help reduce risk of heart disease better than traditional arm cuff readings for some patients, according to preliminary research presented at the American Heart Association's Hypertension 2019 Scientific Sessions.

Heating pads may lower blood pressure in people with high blood pressure when lying down
In people with supine hypertension due to autonomic failure, a condition that increases blood pressure when lying down, overnight heat therapy significantly decreased systolic blood pressure compared to a placebo.

Read More: Blood Pressure News and Blood Pressure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to